Oculis Holding Ag's Cash & cash equivalent grew by 0 % in the Q4 2025 sequentially, while Current Liabilities decreased, this led to improvement in Oculis Holding Ag's Quick Ratio to 2.79, above Oculis Holding Ag average Quick Ratio.

Within Major Pharmaceutical Preparations industry 110 other companies have achieved higher Quick Ratio than Oculis Holding Ag in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 540.

Explain Quick Ratio?
How much Cash & cash equivalents OCS�s has?
What are OCS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

OCS Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	-16.93 %	-5.08 %	-24.67 %	-5.08 %	131.74 %
Y / Y Cash & cash equivalent Change	235.39 %	235.39 %	166.17 %	235.39 %	-32.99 %
Quick Ratio MRQ	2.79	2.21	2.21	2.21	0.69
OCS's Total Ranking	# 540	# 0	#	#	#
Seq. Current Liabilities Change	-20.64 %	26.01 %	-20.64 %	4.68 %	-9.32 %
Seq. Cash & cash equivalent Change	0 %	26.01 %	-20.64 %	235.39 %	-0 %

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 111
Healthcare Sector	# 211
Overall Market	# 540

Quick Ratio Statistics
High	Average	Low
2.21	1.62	0.63
(Dec 31 2025)		(Dec 31 2024)

Financial Statements
Oculis Holding Ag's Current Liabilities	$ 37 Millions	Visit OCS's Balance sheet
Oculis Holding Ag's Cash & cash equivalent	$ 102 Millions	Visit OCS's Balance sheet
Source of OCS's Sales		Visit OCS's Sales by Geography

Cumulative Oculis Holding Ag's Quick Ratio

OCS's Quick Ratio for the trailling 12 Months

OCS Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-12.84 %	4.93 %	26.34 %	66.04 %	118.51 %
Y / Y Cash & cash equivalent TTM Growth	218.08 %	130.82 %	60.8 %	16.01 %	-32.99 %
Quick Ratio TTM	2.34	1.83	1.39	1.03	0.64
Total Ranking TTM	# 1948	# 0	#	#	#
Seq. Current Liabilities TTM Growth	-4.31 %	-1.41 %	-6.4 %	-1.3 %	15.2 %
Seq. Cash & cash equivalent TTM Growth	22.7 %	29.37 %	26.15 %	58.85 %	-10.96 %

Quick ratio ranking by company, industry and sector >> Back to OCS Financial Strength Comparisons >> Go to Compare OCS Quick Ratio to its Competitors

On the trailing twelve months basis OCS Cash & cash equivalent more than doubled by 235.39 % in Q4 2025 year on year, while Current Liabilities faded to $37 millions, this led to increase in in Oculis Holding Ag's Quick Ratio to 2.34, above OCS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 180 other companies have achieved higher Quick Ratio than Oculis Holding Ag. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 1948.

Explain Quick Ratio?
How much Cash & cash equivalents OCS�s has?
What are OCS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 181
Healthcare Sector	# 415
Within the Market	# 1948

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.01	1.74	1.23
(Dec 31 2023)		0

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Scynexis Inc	7.62	$ 40.031 Millions	$ 5.251 Millions
Avalo Therapeutics Inc	7.60	$ 98.373 Millions	$ 12.940 Millions
Milestone Pharmaceuticals Inc	7.58	$ 105.960 Millions	$ 13.979 Millions
Acrivon Therapeutics Inc	7.57	$ 118.582 Millions	$ 15.664 Millions
Annovis Bio Inc	7.54	$ 19.532 Millions	$ 2.591 Millions
Newamsterdam Pharma Company N v	7.40	$ 636.241 Millions	$ 86.036 Millions
Adicet Bio Inc	7.36	$ 158.530 Millions	$ 21.531 Millions
Novabridge Biosciences	7.33	$ 210.842 Millions	$ 28.781 Millions
Day One Biopharmaceuticals Inc	7.29	$ 441.113 Millions	$ 60.522 Millions
Eledon Pharmaceuticals Inc	7.27	$ 133.336 Millions	$ 18.344 Millions
Marker Therapeutics inc	7.07	$ 16.068 Millions	$ 2.274 Millions
Camp4 Therapeutics Corporation	7.06	$ 109.517 Millions	$ 15.514 Millions
Barinthus Biotherapeutics Plc	7.03	$ 70.456 Millions	$ 10.018 Millions
Xenon Pharmaceuticals Inc	7.02	$ 548.886 Millions	$ 78.167 Millions
Stablecoin Development Corporation	6.97	$ 7.958 Millions	$ 1.142 Millions
Centessa Pharmaceuticals Plc	6.86	$ 294.580 Millions	$ 42.935 Millions
Tonix Pharmaceuticals Holding Corp	6.73	$ 207.637 Millions	$ 30.837 Millions
Zentalis Pharmaceuticals Inc	6.73	$ 245.893 Millions	$ 36.559 Millions
An2 Therapeutics Inc	6.65	$ 58.001 Millions	$ 8.720 Millions
Actinium Pharmaceuticals Inc	6.62	$ 47.998 Millions	$ 7.247 Millions
Gain Therapeutics inc	6.45	$ 20.838 Millions	$ 3.233 Millions
Nuvation Bio Inc	6.44	$ 529.211 Millions	$ 82.231 Millions
Vistagen Therapeutics Inc	6.38	$ 80.482 Millions	$ 12.612 Millions
Arcturus Therapeutics Holdings Inc	6.35	$ 230.909 Millions	$ 36.379 Millions
Wave Life Sciences Ltd	6.33	$ 602.068 Millions	$ 95.065 Millions
Korro Bio Inc	6.30	$ 75.156 Millions	$ 11.937 Millions
Rocket Pharmaceuticals Inc	6.25	$ 188.929 Millions	$ 30.206 Millions
Alzamend Neuro Inc	6.22	$ 3.949 Millions	$ 0.635 Millions
Hepion Pharmaceuticals Inc	6.11	$ 1.828 Millions	$ 0.299 Millions
Anebulo Pharmaceuticals Inc	6.09	$ 9.042 Millions	$ 1.486 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.